Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BSC versus photodynamic therapy with ME2906 and PNL6405PLC for peripheral lung cancer
jRCT2031200040Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2020
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of talaporfin sodium in non-small cell lung cancer (NSCLC) and bronchial carcinoma (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Progression-free survival. Started Jun 2020; status: completed.
02
Drugs
talaporfin sodium
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on jRCT2031200040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200040.